Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression

BACKGROUND: Crenolanib is a tyrosine kinase inhibitor targeting PDGFR-α, PDGFR-β and Fms related tyrosine kinase-3 (FLT3) that is currently evaluated in several clinical trials. Although platelet-derived growth factor receptor (PDGFR) signalling pathway is believed to play an important role in angio...

Descripción completa

Detalles Bibliográficos
Autores principales: Berndsen, Robert H., Castrogiovanni, Cédric, Weiss, Andrea, Rausch, Magdalena, Dallinga, Marchien G., Miljkovic-Licina, Marijana, Klaassen, Ingeborg, Meraldi, Patrick, van Beijnum, Judy R., Nowak-Sliwinska, Patrycja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738084/
https://www.ncbi.nlm.nih.gov/pubmed/31235865
http://dx.doi.org/10.1038/s41416-019-0498-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738084/
https://www.ncbi.nlm.nih.gov/pubmed/31235865
http://dx.doi.org/10.1038/s41416-019-0498-2

Ejemplares similares